Statement of Organization, Functions, and Delegations of Authority
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Issuing agencies
Abstract
The Food and Drug Administration (FDA) is correcting a notice entitled "Statement of Organization, Functions, and Delegations of Authority" that appeared in the Federal Register of August 14, 2023. The document announced amendments to the organization structure for FDA, Center for Devices and Radiological Health (CDRH), Office of Strategic Partnerships and Technology Innovation (OST). Although HHS approved these amendments on June 27, 2023, the Notice inadvertently omitted to include the following language: "FDA will not implement the new organizational structure until after the necessary requirements are completed." This document corrects that error.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 160 (Monday, August 21, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 160 (Monday, August 21, 2023)]
[Notices]
[Page 56844]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-18009]
[[Page 56844]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Statement of Organization, Functions, and Delegations of
Authority
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is correcting a notice
entitled ``Statement of Organization, Functions, and Delegations of
Authority'' that appeared in the Federal Register of August 14, 2023.
The document announced amendments to the organization structure for
FDA, Center for Devices and Radiological Health (CDRH), Office of
Strategic Partnerships and Technology Innovation (OST). Although HHS
approved these amendments on June 27, 2023, the Notice inadvertently
omitted to include the following language: ``FDA will not implement the
new organizational structure until after the necessary requirements are
completed.'' This document corrects that error.
FOR FURTHER INFORMATION CONTACT: Denise Huttenlocker, Associate
Director for Management, Office of Management, Center for Devices and
Radiological Health, Food and Drug Administration, Bldg. 66, 10903 New
Hampshire Ave., Silver Spring, MD 20993, 240-743- 1760.
SUPPLEMENTARY INFORMATION: In the Federal Register of August 14, 2023
(88 FR 55053), in FR Doc. 2023-17379, the following corrections are
made:
1. On page 55053, in the second column, in the Dates section, after
the first sentence, add ``FDA will not implement the new organizational
structure until after the necessary requirements are completed.''
2. On page 55053, in the third column, in section III., remove the
first sentence and add in its place, ``After completion of the
necessary requirements for implementation, this reorganization will be
reflected in FDA's Staff Manual Guide (SMG).''
Dated: August 17, 2023.
Elizabeth J. Gramling,
Executive Secretary to the Department, Department of Health and Human
Services.
[FR Doc. 2023-18009 Filed 8-17-23; 4:15 pm]
BILLING CODE 4164-01-P
</pre></body>
</html>This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.